RxDoctor Payments DataLook up a doctor →

Robert Laugherty, PA

Physician Assistant · Alcoa, TNNPI 1932368552

Payments from drug & device makers

$122,299in general payments, 2019–2025

Across 705 payments — averaging $173.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$59K
  • Amgen$23K
  • Eli Lilly$16K
  • UCB, Inc.$15K
  • Johnson & Johnson$3K
  • AbbVie$2K
  • plus $4K from 15 others

What the payments were for

  • Consulting fees$9,1287%
  • Speaking & faculty fees$83,05868%
  • Travel & lodging$17,15014%
  • Food & beverage$12,50510%
  • Education$4590%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,299 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$79,068
Medicare patients
336
Services billed
3,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept55$506,995
RinvoqUpadacitinib71$462,713
Humira(Cf) PenAdalimumab47$448,920
EnbrelEtanercept51$413,815
OrenciaAbatacept31$211,761
Cimzia (2 Pack)Certolizumab Pegol30$192,969
Humira(Cf)Adalimumab21$177,385
Taltz AutoinjectorIxekizumab23$160,491
XeljanzTofacitinib Citrate25$153,127
Xeljanz XrTofacitinib Citrate25$143,521
Orencia ClickjectAbatacept18$98,391
Cosentyx Sensoready (2 Pens)Secukinumab11$88,935
ProliaDenosumab40$68,642
OtezlaApremilast14$63,613
KevzaraSarilumab12$52,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$2,195$640,09892 claims
AmgenEnbrel, Prolia, Otezla$23,273$546,069105 claims
E.r. Squibb & Sons, L.L.C.Orencia$91$211,76131 claims
UCB, Inc.Cimzia (2 Pack)$15,307$192,96930 claims
PfizerXeljanz$500$153,12725 claims
SanofiKevzara$751$52,05912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Alcoa

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →